Clinical trials
GVHD - Graft-Versus-Host Disease clinical trials
Below are recruiting gvhd - graft-versus-host disease clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07127926RecruitingPhase 1
Belumosudil pill vs crushed pill study for chronic GVHD
This trial tests whether crushing belumosudil tablets changes how the drug works in people with chronic graft-versus-host-disease (GVHD), a complication after a stem cell transplant. It helps doctors know if taking crushed pills is as effective as whole tablets.
Houston, TexasAges 18 years+ - NCT04700657Recruiting
Study dryness patterns in eye graft-vs-host disease
This study looks at how common and how severe corneal nerve-related dryness is in people with chronic graft-vs-host disease (GVHD) after a stem cell transplant. It may help doctors understand which eye problems are most typical and how best to recognize them early.
Indianapolis, IndianaAges 18 years+ - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT03148743Recruiting
Fecal transplant for gut graft-versus-host disease
This study tests whether a fecal transplant (FMT) can help treat gut graft-versus-host disease (gut GVHD), a condition where donated immune cells attack the intestines. If you have gut GVHD and meet age requirements, you may be eligible to receive this treatment in the trial.
Suzhou, JiangsuAges 10–60 - NCT05718791Recruiting
Testing blood markers to predict graft-versus-host disease
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
Detroit, MichiganAges 18–80 - NCT05067595RecruitingPhase 1
Fecal transplant plus fiber for gut graft-versus-host disease
This Phase 1 study tests whether a fecal microbiota transplant (a stool-based treatment from a screened donor) plus a dietary fiber supplement can improve gut symptoms after a bone marrow transplant. It is aimed at people with mild to severe gut graft-versus-host disease (GVHD).
Seattle, WashingtonAges 18 years+ - NCT06904599RecruitingPhase 2
Testing hCG for acute GVHD after a stem cell transplant
This study tests if a hormone called hCG can help treat moderate-to-severe graft-versus-host disease (GVHD) after a stem cell transplant. It is for adults who have recently developed GVHD and need steroids, but have not been on high-dose steroids for long.
Monterrey, Nuevo LeónAges 18 years+ - NCT07025538RecruitingPhase 1
Preventing chronic graft-versus-host disease with ruxolitinib
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
Duarte, CaliforniaAges 18 years+ - NCT07325253RecruitingPhase 2
PET scan study for chronic graft versus host disease
This trial uses a special PET scan to see if we can better understand chronic graft versus host disease (cGVHD), a complication after a stem cell transplant. The study is for people with joint stiffness caused by cGVHD, and it may help doctors find new ways to manage symptoms.
Houston, TexasAges 18 years+ - NCT06991361RecruitingPhase 1
Expanded immune cells and low-dose IL-2 for chronic GVHD
This trial tests whether giving special immune cells (regulatory T cells) grown in a lab, along with a low dose of interleukin-2, can help people with chronic graft-versus-host disease (GVHD) that hasn't improved with steroids. GVHD is a complication after a stem cell transplant where donor cells attack the patient's body.
Boston, MassachusettsAges 2 years+ - NCT06247150Recruiting
Study of immune cells in graft-versus-host disease after stem cell transplant
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
PessacAges 18 years+ - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Tampa, FloridaAges 1–60 - NCT04380740RecruitingPhase 2
Longer vs shorter abatacept doses to prevent graft-versus-host disease
This trial tests whether giving abatacept for a longer or shorter time can better prevent graft-versus-host disease (a common complication after a stem cell transplant). If you’re having a planned unrelated donor transplant, the results may help reduce the risk or severity of transplant-related immune problems.
Duarte, CaliforniaAges 2 years+ - NCT04660487Recruiting
How diet carbs affect GVHD after bone marrow transplant
This study looks at whether certain types of gut carbohydrates (called FODMAPs) are linked to graft-versus-host disease (GVHD) after a bone marrow transplant. It may help doctors understand how diet could influence symptoms and outcomes for people with specific blood cancers.
Suzhou, JiangsuAges 18–60 - NCT04710576RecruitingPhase 2
Axatilimab for chronic graft-versus-host disease
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
Birmingham, AlabamaAges 2 years+ - NCT04744116RecruitingEarly Phase 1
Cord blood cell therapy added to ruxolitinib for steroid-resistant GVHD
This trial studies whether adding cord-blood–derived cells to ruxolitinib can improve steroid-resistant acute graft-versus-host disease (GVHD) affecting the lower gut or liver. It’s meant for people who are not getting better (or are worsening) despite adequate steroid treatment.
Houston, TexasAges 12–80 - NCT05236062Recruiting
Exercise during steroid treatment for GVHD
This study looks at whether doing moderate-to-vigorous exercise can reduce complications from corticosteroids in people with newly diagnosed GVHD. It may help your body tolerate steroids better, while checking exercise safety during treatment.
Boston, MassachusettsAges 18 years+ - NCT05333367Recruiting
Study of how a light treatment causes immune cell death
This trial looks at how “extracorporeal photochemotherapy” (a light-based treatment done outside the body) works at the cellular level. It may help improve treatment and control for people dealing with immune reactions after transplant or certain blood/skin conditions.
BesançonAges 18–85 - NCT05866302Recruiting
CT breathing-scan test to detect chronic lung injury after transplant
This study uses a special way to analyze breathing-related CT images to find early or ongoing lung injury after an allogeneic stem cell transplant. It may help clinicians recognize chronic lung complications sooner and better guide care.
Stanford, CaliforniaAges 3 years+ - NCT05996627RecruitingPhase 2
Belumosudil for early treatment of chronic graft-versus-host disease
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
Duarte, CaliforniaAges 18 years+ - NCT06233110RecruitingPhase 1
Ruxolitinib and fostamatinib for steroid-resistant chronic GVHD
This study tests two drugs, ruxolitinib and fostamatinib, together for people with chronic graft-versus-host disease (GVHD) that hasn't responded well to steroids. The goal is to see if this combination can better control GVHD.
Durham, North CarolinaAges 18–80 - NCT06252870RecruitingPhase 2
Comparing two conditioning regimens for stem cell transplant
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
AngersAges 18–70 - NCT06568328RecruitingPhase 1
Experimental cell therapy for severe graft-versus-host disease
This trial tests a new immune cell treatment for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard medications like ruxolitinib. The goal is to see if these special cells can calm the immune attack and help manage symptoms.
Fuzhou, FujianAges 1–70 - NCT06815003RecruitingPhase 2
Preventing Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Duarte, CaliforniaAges 18–80
Hear when a new GVHD - Graft-Versus-Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gvhd - graft-versus-host disease?
- Yes. Clin2 currently lists 35 recruiting gvhd - graft-versus-host disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gvhd - graft-versus-host disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gvhd - graft-versus-host disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.